BTIG Defends bluebird bio (BLUE) Amid ASH Abstracts Sell-Off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
bluebird bio (BLUE) ASH Abstract Data Fairly Consistent With Previously Published Data - Leerink
November 3, 2016 11:58 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and $80 price target on bluebird bio (NASDAQ: BLUE) saying the ASH abstract data was fairly consistent with previously published data.
Schmidt commented, " This morning, abstracts for the upcoming American Society of Hematology (ASH) Annual Meeting were... More
Cantor Fitzgerald Reiterates Sell on bluebird bio (BLUE) Following ASH Abstracts
November 3, 2016 11:19 AM EDTCantor Fitzgerald analyst Elemer Piros reiterated a Sell rating and $37 price target on bluebird bio (NASDAQ: BLUE) following this morning's ASH abstracts.
Piros highlighted:
As telegraphed by the company at a recent investor/analyst day, at the upcoming ASH... Morebluebird bio (BLUE) to Present New Data from Three LentiGlobin Studies at ASH
November 3, 2016 9:04 AM EDTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data from its ongoing clinical studies of LentiGlobin drug product in transfusion-dependent -thalassemia (TDT) and severe sickle cell disease (SCD) will be highlighted in oral and poster presentations... More
